A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs LHW 090 (Primary)
- Indications Resistant hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 22 Jul 2017 This trial has been suspended in Germany.
- 11 Jul 2017 Planned End Date changed from 13 Oct 2017 to 16 Aug 2017.
- 11 Jul 2017 Planned primary completion date changed from 13 Oct 2017 to 16 Aug 2017.